Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00571675

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

Hormone Refractory Prostate Cancer Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo in the treatment of chemotherapy-naïve metastatic hormone-refractory prostate cancer, who have received hormonal therapy but not chemotherapy.

Clinical Trial Description

Further Study Details provided by Ascenta. ;

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00571675
Study type Interventional
Source Ascenta Therapeutics
Contact
Status Completed
Phase Phase 2
Start date October 2007
Completion date September 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT00069745 - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen Phase 3
Completed NCT01260688 - Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel Phase 2
Withdrawn NCT02867345 - PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
Completed NCT01741116 - Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer Phase 2
Recruiting NCT00795171 - Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer Phase 2
Terminated NCT00525408 - A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer Phase 2
Completed NCT00667199 - BAY88-8223, Does Response Study in HRPC Patients Phase 2
Recruiting NCT02955082 - The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment Phase 2
Recruiting NCT01590498 - Radiotherapy vs Observation for CRPC N/A
Completed NCT01518283 - Study of Weekly Cabazitaxel for Advanced Prostate Cancer Phase 2
Terminated NCT00906243 - RNActive®-Derived Therapeutic Vaccine Phase 1/Phase 2
Terminated NCT00493766 - Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone Phase 1
Terminated NCT01083615 - A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Phase 3
Completed NCT00987753 - Study Evaluating the Safety and Tolerability of L-377202 Phase 1/Phase 2
Recruiting NCT02208583 - Molecular Phenotype Changes and Personalized Treatment for CRPC N/A
Completed NCT00928252 - Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer Phase 1/Phase 2
Completed NCT00699751 - A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases Phase 3
Recruiting NCT00411853 - Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients Phase 2
Active, not recruiting NCT00448734 - A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer Phase 1/Phase 2
Completed NCT00510718 - A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer Phase 1